“But I don't believe for one minute that any CYD
Post# of 148179
The CYDY engineers filed a cancer BTD with data from 2 patients and filed an incomplete BLA that they knew was incomplete. So, no, it’s not hard to believe that they don’t understand other potential pathways for leronlimab.